Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

UNCY vs CNTB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

UNCY Captures Overall Composite Edge (43.7 HOLD vs 41.0 SELL), While CNTB Leads 4–1 on Growth & Valuation Pillars

UNCY Overall Winner 6-Pillar Tally: UNCY 1 – 4 CNTB (1 Tie) Matrix Metrics: UNCY 6 – 3 CNTB

As of Nov 17, 2026, Unicycive Therapeutics, Inc. (UNCY) captures the overall head-to-head institutional edge over Connect Biopharma Holdings Limited (CNTB) on higher Unified Composite conviction (43.7/100 HOLD vs. 41.0/100 SELL) after splitting the core matrix 6–3 (led by Profitability & Quality), while CNTB wins 4–1 across the 6-pillar growth and valuation breakdown. UNCY trades at $3.74 (2.5x Forward P/E, 0.0% operating margin) versus CNTB at $0.59 (0.8x Forward P/E, -2384.5% operating margin).

  • Growth vs. Quality Trade-Off: UNCY earns the overall head-to-head edge with a stronger Unified Composite Score (43.7/100 HOLD vs. CNTB 41.0/100 SELL) and 1.02β · 65% Vol risk profile, whereas CNTB leads top-line expansion (+5666.7% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: UNCY is currently in a Breakdown options structure phase (RSI 47.6); meanwhile CNTB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About UNCY vs CNTB
UNCY NASDAQ Head-to-Head Winner
Unicycive Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.74
+1.08% 1D
Market Cap $97.2M
TTM Revenue N/A
Forward P/E 2.5x
Beta / 30D Vol 1.02β · 65% Vol
Unified Composite Score
43.7 / 100 HOLD
Tech 30.0 Fund 50.0 Flow 70.0 Mom 58.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 47.6 · SMA20: $3.69 · SMA50: $4.14
CNTB NASDAQ
Connect Biopharma Holdings Limited Ordinary Shares
Pharmaceutical Preparations
$0.59
-7.94% 1D
Market Cap $42.6M
TTM Revenue $3.0M
Forward P/E 0.8x
Beta / 30D Vol 0.92β · 68% Vol
Unified Composite Score
41.0 / 100 SELL
Tech 25.0 Fund 48.0 Flow 66.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -38.7%), weak momentum, RSI 26
RSI-14: 25.6 · SMA20: $0.75 · SMA50: $0.99

6-Pillar Scorecard Institutional Category Breakdown (UNCY 1 – 4 CNTB)

Columns: Metric · UNCY · CNTB
1. Valuation Multiples CNTB
Forward P/E 2.5x 0.8x
Trailing P/E 2.0x 0.8x
PEG Ratio N/M N/M
EV / Revenue N/M 5.5x
2. Growth & Scale CNTB
Revenue Growth (YoY) +0.0% +5666.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $3.0M
Market Cap $97.2M $42.6M
3. Profitability & Quality UNCY
Gross Margin N/A 100.0%
Operating Margin 0.0% -2384.5%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -101.1% -140.5%
4. Balance Sheet & Cash Flow CNTB
Cash Generation (TTM) -$28M -$61M
Cash Flow Margin N/A N/A
Net Cash / Leverage $43M Net Cash $26M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CNTB
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 79.1% (30th %ile) 397.3% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: UNCY (6) vs CNTB (3)
Institutional Metric UNCY CNTB Criterion Row Edge
Market Capitalization
Scale
$97.2M $42.6M Larger Scale UNCY
Trailing P/E Ratio
Valuation
2.0x 0.8x Lower Multiple CNTB
Forward P/E Ratio
Valuation
2.5x 0.8x Lower Multiple CNTB
Revenue Growth (YoY)
Growth
+0.0% +5666.7% Higher Growth CNTB
Operating Margin (TTM)
Profitability
0.0% -2384.5% Higher Margin UNCY
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-101.1% -140.5% Higher ROE UNCY
52-Week Range Position
Momentum
8% ($3–$9) 1% ($1–$4) Stronger Trend UNCY
Beta / 30D Volatility
Risk Regime
1.02β · 65% Vol 0.92β · 68% Vol Lower Realized Risk UNCY
Unified Institutional Score
Composite Signal
43.7 / 100 (HOLD) 41.0 / 100 (SELL) Higher Composite UNCY
Trailing 12M Revenue (USD)
Operating Scale
N/A $3.0M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 5.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$28M ($43M Net Cash) -$61M ($26M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon UNCY +40.77 pp
UNCY: +6.55% · CNTB: -34.22%
3M Horizon UNCY +42.97 pp
UNCY: -32.97% · CNTB: -75.94%
6M Horizon UNCY +21.35 pp
UNCY: -51.62% · CNTB: -72.97%
1Y Horizon UNCY +38.04 pp
UNCY: -34.04% · CNTB: -72.08%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period UNCY Revenue CNTB Revenue UNCY Op. Margin CNTB Op. Margin Margin Leader
FY2022 $0M N/A -1898.2% N/A UNCY
FY2023 $0M N/A -3077.6% N/A UNCY
FY2024 N/A $30M N/A -86.2% CNTB
FY2025 N/A $0M N/A -90740.6% CNTB

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
UNCY BREAKDOWN
129d in phase · OBV NEUTRAL
Current IV 79.1%
IV Percentile 30th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact UNCY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CNTB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 397.3%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CNTB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
UNCY Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $97.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CNTB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $42.6M market capitalization and -2384.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ UNCY vs CNTB Key Questions & Quantitative Answers

As of Nov 17, 2026, Unicycive Therapeutics, Inc. (UNCY) captures the overall head-to-head institutional edge over Connect Biopharma Holdings Limited (CNTB) on higher Unified Composite conviction (43.7/100 HOLD vs. 41.0/100 SELL) after splitting the core matrix 6–3 (led by Profitability & Quality), while CNTB wins 4–1 across the 6-pillar growth and valuation breakdown. UNCY trades at $3.74 (2.5x Forward P/E, 0.0% operating margin) versus CNTB at $0.59 (0.8x Forward P/E, -2384.5% operating margin). Growth vs. Quality Trade-Off: UNCY earns the overall head-to-head edge with a stronger Unified Composite Score (43.7/100 HOLD vs. CNTB 41.0/100 SELL) and 1.02β · 65% Vol risk profile, whereas CNTB leads top-line expansion (+5666.7% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: UNCY is currently in a Breakdown options structure phase (RSI 47.6); meanwhile CNTB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CNTB leads the Growth & Scale pillar: UNCY posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CNTB at +5666.7% YoY revenue growth and +0.0% YoY earnings growth on $3.0M TTM revenue (100.0% gross margin, -2384.5% operating margin). Across the 4-period historical trajectory (FY2022 to FY2025), UNCY cumulative revenue shifted N/A while CNTB shifted N/A. In operating R&D and SG&A reinvestment, UNCY deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CNTB.

CNTB screens cheaper on headline valuation multiples. UNCY trades at 2.5x Forward P/E, 2.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CNTB trades at 0.8x Forward P/E, 0.8x Trailing P/E, N/M PEG, and 5.5x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against UNCY (-101.1% ROE) versus CNTB (-140.5% ROE) capital efficiency.

In options market volatility and institutional positioning, UNCY carries 79.1% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.02β · 65% Vol realized risk). By comparison, CNTB carries 397.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.92β · 68% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.